Skip to content
Screener

Arbutus Biopharma Corporation ABUS Q1 2026 earnings

Reported May 13, 2026 · Before market open

Revenue$179.1MBeat by $178.4M
EPS$0.87Beat by $0.90
Revenue estimate$750.0K
EPS estimate-$0.03

Next report

Nov 16, 2026 (in a month)
Revenue estimate$1.0M
EPS estimate-$0.02

Financials

Q1 2026

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$879.65M+31.6%
Enterprise value$856.58M+35.5%
P/E5.5×—
P/S4.6×-99.8×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Segments

By product

See full
Revenue from collaborations and licenses$178.7M+21,912%
Non-cash royalty revenue$181.0K-59.6%

By segment

See full
Reportable Segment$179.1M+10,055%

FAQ

When did Arbutus Biopharma Corporation report Q1 2026 earnings?
Arbutus Biopharma Corporation (ABUS) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Arbutus Biopharma Corporation's Q1 2026 revenue and EPS?
Arbutus Biopharma Corporation reported revenue of $179.1M and eps of $0.87 for Q1 2026.
Did Arbutus Biopharma Corporation beat estimates in Q1 2026?
Revenue beat the consensus estimate of $750.0K by $178.4M. EPS beat the consensus estimate of $-0.03 by $0.90.
How did Arbutus Biopharma Corporation's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10054.5% from $1.8M a year earlier.
Where can I find Arbutus Biopharma Corporation's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-003346) and the 10-Q periodic report (0001447028-26-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.